USSTOCK.TODAY
Market Closed
Log in Sign up

Summit Therapeutics shares plunge following FDA rejection

The Motley Fool · ·by G4L

SMMT
SMMT Summit Therapeutics Inc
$10.67 -9.73%
View chart & analysis →
  1. 1Summit Therapeutics shares fell more than 20% in pre-market trading.
  2. 2The U.S. Food and Drug Administration issued a CRL regarding Summit Therapeutics' drug approval application.
  3. 3Approval was denied despite confirming a 24% reduction in the risk of death for ivonescimab.

So what's the key point?

Summit Therapeutics shares fell by more than 20% during pre-market trading.

Source The Motley Fool · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →